Phibro Animal Health Corp Class A (PAHC) valuation
Phibro Animal Health P/E ratio history
Phibro Animal Health trades at 16.0 times its earnings over the last twelve months and 11.1 times the earnings analysts expect over the next twelve. At its last 10 fiscal year ends its P/E ranged from 12.9 (year to Jun 2026) to 279.5 (year to Jun 2024), with a median of 22.3.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Jun 30, 2026 | $31.40 | $2.43 | 12.9 | 9.6 |
| Jun 30, 2025 | $25.54 | $1.19 | 21.5 | 11.6 |
| Jun 30, 2024 | $16.77 | $0.06 | 279.5 | — |
| Jun 30, 2023 | $13.70 | $0.81 | 16.9 | — |
| Jun 30, 2022 | $19.13 | $1.21 | 15.8 | 14.3 |
| Jun 30, 2021 | $28.88 | $1.34 | 21.6 | 22.3 |
| Jun 30, 2020 | $26.27 | $0.83 | 31.7 | — |
| Jun 30, 2019 | $31.77 | $1.35 | 23.5 | — |
| Jun 30, 2018 | $46.05 | $1.61 | 28.6 | — |
| Jun 30, 2017 | $37.05 | $1.61 | 23.0 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Phibro Animal Health valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Phibro Animal HealthPAHC | $1.58B | 16.0 | 11.1 | 1.0 |
| First Tracks BiotherapeuticsTRAX | $1.57B | — | — | — |
| InnovivaINVA | $1.57B | 4.9 | 9.4 | 3.6 |
| Urogen PharmaURGN | $1.59B | — | 28.0 | 8.5 |
| Teladoc HealthTDOC | $1.54B | — | — | 0.6 |
| Sonida Senior LivingSNDA | $1.62B | — | — | 3.1 |
| NovocureNVCR | $1.53B | — | — | 2.1 |
| Ocular TherapeutixOCUL | $1.53B | — | — | 29.3 |
| Stoke TherapeuticsSTOK | $1.64B | — | — | 59.3 |
| Peer median | 4.9 | 18.7 | 3.6 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: PAHC financials · PAHC returns
No forecast, no recommendation. This page describes Phibro Animal Health Corp Class A from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.